Device Trial Radar · NCT07575828
Outcomes of an Optimized Workflow With PulseSelect Pulsed Field Ablation (PFA) System in Paroxysmal and Persistent Atrial Fibrillation
Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
320
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Aug 2028
Study completion Mar 2029
Sponsor
- Lead sponsor
- Medtronic Cardiac Ablation SolutionsPublic (MDT)
- Sponsor type
- Industry
- First posted
- May 8, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The NEXT PULSE study is a pre-market, prospective, multi-center, non-randomized, interventional clinical study. Adult subjects with symptomatic paroxysmal or persistent AF who provided consent will be enrolled and treated with the PulseSelect PFA System.
Conditions
- Paroxysmal Atrial Fibrillation (PAF)
- Persistent Atrial Fibrillation
Interventions
PulseSelect Pulse Field Ablation (PFA) SystemDevice
Adult subjects with recurrent symptomatic paroxysmal AF or persistent AF will be enrolled and undergo ablation with the PulseSelect™ PFA system.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: Number of Participants with at Least One Primary Safety EventTime frame: Up to 6 months post procedure
- Effectiveness: Number of Participants with Treatment SuccessTime frame: Up to 12 months post procedure
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.